Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development of targeted inhibitors for the treatment of hematologic and solid cancers. The Company’s lead programs are Vecabrutinib, a selective non-covalent inhibitor of Bruton’s Tyrosine Kinase (BTK) inhibitors is in Phase Ib/II clinical trial. The Company is also developing SNS-510, a phosphoinositide dependent protein kinase 1 (PDK1) inhibitor and TAK-580 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. The Company also offers Vosaroxin, an anticancer quinolone derivative (AQD), which is used for the treatment of acute myeloid leukemia (AML).